デフォルト表紙
市場調査レポート
商品コード
1318007

代謝異常治療薬市場:疾患タイプ別、製品別-2023-2030年の世界予測

Metabolic Disorders Therapeutics Market by Disease Type, Product - Cumulative Impact of COVID-19, Russia Ukraine Conflict, and High Inflation - Global Forecast 2023-2030

出版日: | 発行: 360iResearch | ページ情報: 英文 186 Pages | 納期: 即日から翌営業日

● お客様のご希望に応じて、既存データの加工や未掲載情報(例:国別セグメント)の追加などの対応が可能です。  詳細はお問い合わせください。

価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=158.16円
代謝異常治療薬市場:疾患タイプ別、製品別-2023-2030年の世界予測
出版日: 2023年06月12日
発行: 360iResearch
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
ご注意事項 :
本レポートは最新情報反映のため適宜更新し、内容構成変更を行う場合があります。ご検討の際はお問い合わせください。
  • 全表示
  • 概要
  • 図表
  • 目次
概要

代謝異常治療薬の世界市場は、2023年にCAGR 8.80%で614億1,000万米ドル、2030年には1,110億4,000万米ドルに達すると予測され、大きく成長すると予測されています。

FPNVポジショニング・マトリックス

FPNVポジショニングマトリックスは世界の代謝異常治療薬市場を評価するために不可欠です。事業戦略と製品満足度の主要指標を調査することで、ベンダーの包括的な評価を提供し、ユーザーは特定のニーズに基づいた情報をもとに意思決定を行うことができます。この高度な分析により、ベンダーは成功の度合いが異なる4つの象限に整理されます:フォアフロント(F)、パスファインダー(P)、ニッチ(N)、バイタル(V)です。

市場シェア分析

市場シェア分析では、特定の市場領域におけるベンダーの現状を洞察することができます。全体的な収益、顧客基盤、その他の主要指標に対するベンダーの貢献度を比較することで、企業が市場シェアを争う際に、自社の業績や直面している状況をより深く理解することができます。また、本分析では、調査した基準年において、特定のセクターがどの程度競合しているのか、蓄積、断片化の優位性、合併の特徴についても明らかにしています。

本レポートは、以下のポイントに関する洞察を提供します:

1.市場の浸透度:主要企業が提供する市場に関する包括的な情報を提供します。

2.市場の発展:有利な新興市場に関する詳細情報を提供し、市場の成熟セグメントにおける浸透度を分析します。

3.市場の多様化:新製品の上市、未開発地域、最近の開発、投資に関する詳細情報を提供します。

4.市場の動向:COVID-19、ロシア・ウクライナ紛争、高インフレの累積的な影響を包括的に理解することができます。

5.競合の評価と情報:主要企業の市場シェア、戦略、製品、認証、規制状況、特許状況、製造能力を網羅的に評価します。

6.製品開発およびイノベーション:将来技術、研究開発活動、画期的な製品開発に関する知的洞察を提供します。

本レポートは、以下のような質問にお答えします:

1.代謝異常治療薬の世界市場規模および予測は?

2.予測期間中、世界の代謝異常治療薬市場を形成するCOVID-19の阻害要因と影響は?

3.代謝異常治療薬の世界市場において予測期間中に投資すべき製品/セグメント/アプリケーション/分野は?

4.代謝異常治療薬の世界市場における競争戦略は?

5.代謝異常治療薬の世界市場における技術動向と規制の枠組みは?

6.代謝異常治療薬の世界市場における主要ベンダーの市場シェアは?

7.代謝異常治療薬の世界市場への参入には、どのような形態や戦略的な動きが適していると考えられるか?

目次

第1章 序文

第2章 調査手法

第3章 エグゼクティブサマリー

第4章 市場の概要

第5章 市場洞察

  • 市場力学
    • 促進要因
      • 代謝異常症の治療に対する意識の高まり
      • 増加する人口におけるさまざまな代謝性疾患の有病率
      • 代謝異常症の検査と診断の改善
    • 抑制要因
      • 高額な治療費と償還の欠如
    • 機会
      • 新たな治療法の開発のための資金の増加
      • 代謝障害治療における遺伝子治療の可能性
    • 課題
      • 厳格な政府承認基準と規制
  • 市場動向
  • COVID-19の累積的な影響
  • ロシア・ウクライナ紛争の累積的影響
  • 高インフレの累積的影響
  • ポーターのファイブフォース分析
  • バリューチェーンとクリティカルパス分析
  • 規制の枠組み
  • 顧客のカスタマイズ

第6章 代謝異常治療薬市場:疾患タイプ別

  • 糖尿病
  • 高コレステロール血症
  • リソソーム蓄積症
  • 肥満

第7章 代謝異常治療薬市場:製品別

  • 球状白質ジストロフィー
  • 肝性脳症
  • 異染性白質ジストロフィー

第8章 南北アメリカの代謝異常治療薬市場

  • アルゼンチン
  • ブラジル
  • カナダ
  • メキシコ
  • 米国

第9章 アジア太平洋地域の代謝異常治療薬市場

  • オーストラリア
  • 中国
  • インド
  • インドネシア
  • 日本
  • マレーシア
  • フィリピン
  • シンガポール
  • 韓国
  • 台湾
  • タイ
  • ベトナム

第10章 欧州・中東・アフリカの代謝異常治療薬市場

  • デンマーク
  • エジプト
  • フィンランド
  • フランス
  • ドイツ
  • イスラエル
  • イタリア
  • オランダ
  • ナイジェリア
  • ノルウェー
  • ポーランド
  • カタール
  • ロシア
  • サウジアラビア
  • 南アフリカ
  • スペイン
  • スウェーデン
  • スイス
  • トルコ
  • アラブ首長国連邦
  • 英国

第11章 競合情勢

  • FPNVポジショニングマトリクス
  • 市場シェア分析:主要企業別
  • 競合シナリオ分析:主要企業別

第12章 掲載企業一覧

第13章 付録

  • ディスカッションガイド
  • ライセンスと価格について
図表

LIST OF FIGURES

  • FIGURE 1. METABOLIC DISORDERS THERAPEUTICS MARKET RESEARCH PROCESS
  • FIGURE 2. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2022 VS 2030
  • FIGURE 3. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2030 (%)
  • FIGURE 5. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2030 (%)
  • FIGURE 6. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY REGION, 2022 VS 2030 (%)
  • FIGURE 7. METABOLIC DISORDERS THERAPEUTICS MARKET DYNAMICS
  • FIGURE 8. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 9. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 10. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 11. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 12. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 13. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2022 VS 2023 VS 2030 (USD MILLION)
  • FIGURE 14. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • FIGURE 15. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022

LIST OF TABLES

  • TABLE 1. METABOLIC DISORDERS THERAPEUTICS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2022
  • TABLE 3. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 5. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DIABETES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 6. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HYPERCHOLESTEROLEMIA, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 7. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY LYSOSOMAL STORAGE DISEASE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 8. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY OBESITY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 10. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY GLOBOID LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 11. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY HEPATIC ENCEPHALOPATHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY METACHROMATIC LEUKODYSTROPHY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 14. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 15. AMERICAS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 16. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 17. ARGENTINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 18. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 19. BRAZIL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 20. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 21. CANADA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 22. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 23. MEXICO METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 24. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 25. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 26. UNITED STATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 27. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 28. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 29. ASIA-PACIFIC METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 30. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 31. AUSTRALIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 32. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 33. CHINA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 34. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 35. INDIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 36. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 37. INDONESIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 38. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 39. JAPAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 40. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 41. MALAYSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 42. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 43. PHILIPPINES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 44. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 45. SINGAPORE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 46. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 47. SOUTH KOREA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 48. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 49. TAIWAN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 50. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 51. THAILAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 52. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 53. VIETNAM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 54. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 55. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 56. EUROPE, MIDDLE EAST & AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 57. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 58. DENMARK METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 59. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 60. EGYPT METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 61. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 62. FINLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 63. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 64. FRANCE METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 65. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 66. GERMANY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 67. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 68. ISRAEL METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 69. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 70. ITALY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 71. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 72. NETHERLANDS METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 73. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 74. NIGERIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 75. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 76. NORWAY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 77. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 78. POLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 79. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 80. QATAR METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 81. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 82. RUSSIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 83. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 84. SAUDI ARABIA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 85. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 86. SOUTH AFRICA METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 87. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 88. SPAIN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 89. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 90. SWEDEN METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 91. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 92. SWITZERLAND METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 93. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 94. TURKEY METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 95. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 96. UNITED ARAB EMIRATES METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 97. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY DISEASE TYPE, 2018-2030 (USD MILLION)
  • TABLE 98. UNITED KINGDOM METABOLIC DISORDERS THERAPEUTICS MARKET SIZE, BY PRODUCT, 2018-2030 (USD MILLION)
  • TABLE 99. METABOLIC DISORDERS THERAPEUTICS MARKET, FPNV POSITIONING MATRIX, 2022
  • TABLE 100. METABOLIC DISORDERS THERAPEUTICS MARKET SHARE, BY KEY PLAYER, 2022
  • TABLE 101. METABOLIC DISORDERS THERAPEUTICS MARKET LICENSE & PRICING
目次
Product Code: MRR-0363DFE03689

The Global Metabolic Disorders Therapeutics Market is forecasted to grow significantly, with a projected USD 61.41 billion in 2023 at a CAGR of 8.80% and expected to reach a staggering USD 111.04 billion by 2030.

The Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and High Inflation is expected to have significant long-term effects on the Global Metabolic Disorders Therapeutics Market. The ongoing research considers the changes in consumer behavior, supply chain disruptions, and government interventions caused by the pandemic. Similarly, the report considers the ongoing political and economic uncertainty in Eastern Europe caused by the Russia-Ukraine Conflict and its potential implications for demand-supply balances, pressure on pricing variants, and import/export and trading. Additionally, the report addresses the impact of High Inflation on the global economy and details fiscal policies measuring and reducing its effects on demand, supply, cash flow, and currency exchange.

Market Segmentation & Coverage:

This research report categorizes the Global Metabolic Disorders Therapeutics Market in order to forecast the revenues and analyze trends in each of following sub-markets:

Based on Disease Type, market is studied across Diabetes, Hypercholesterolemia, Lysosomal Storage Disease, and Obesity. The Hypercholesterolemia is projected to witness significant market share during forecast period.

Based on Product, market is studied across Globoid Leukodystrophy, Hepatic Encephalopathy, and Metachromatic Leukodystrophy. The Globoid Leukodystrophy is projected to witness significant market share during forecast period.

Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom. The Americas commanded largest market share of 38.75% in 2022, followed by Europe, Middle East & Africa.

Market Statistics:

The report provides market sizing and forecasts across 7 major currencies - USD, EUR, JPY, GBP, AUD, CAD, and CHF; multiple currency support helps organization leaders to make well-informed decisions. In this report, 2018 to 2021 are considered as historical years, 2022 is base year, 2023 is estimated year, and years from 2024 to 2030 are considered as forecast period.

FPNV Positioning Matrix:

The FPNV Positioning Matrix is essential for assessing the Global Metabolic Disorders Therapeutics Market. It provides a comprehensive evaluation of vendors by examining key metrics within Business Strategy and Product Satisfaction, allowing users to make informed decisions based on their specific needs. This advanced analysis then organizes these vendors into four distinct quadrants, which represent varying levels of success: Forefront (F), Pathfinder (P), Niche (N), or Vital(V).

Market Share Analysis:

The Market Share Analysis offers an insightful look at the current state of vendors in a particular market space. By comparing vendor contributions to overall revenue, customer base, and other key metrics, we can give companies a greater understanding of their performance and what they are up against when competing for market share. The analysis also sheds light on just how competitive any given sector is about accumulation, fragmentation dominance, and amalgamation traits over the base year period studied.

The report provides insights on the following pointers:

1. Market Penetration: Provides comprehensive information on the market offered by the key players

2. Market Development: Provides in-depth information about lucrative emerging markets and analyzes penetration across mature segments of the markets

3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments

4. Market Trends: Provides comprehensive understanding of the Cumulative Impact of COVID-19, the Russia-Ukraine Conflict, and the High Inflation

5. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players

6. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments

The report answers questions such as:

1. What is the market size and forecast of the Global Metabolic Disorders Therapeutics Market?

2. What are the inhibiting factors and impact of COVID-19 shaping the Global Metabolic Disorders Therapeutics Market during the forecast period?

3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Metabolic Disorders Therapeutics Market?

4. What is the competitive strategic window for opportunities in the Global Metabolic Disorders Therapeutics Market?

5. What are the technology trends and regulatory frameworks in the Global Metabolic Disorders Therapeutics Market?

6. What is the market share of the leading vendors in the Global Metabolic Disorders Therapeutics Market?

7. What modes and strategic moves are considered suitable for entering the Global Metabolic Disorders Therapeutics Market?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Limitations
  • 1.7. Assumptions
  • 1.8. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

  • 4.1. Introduction
  • 4.2. Metabolic Disorders Therapeutics Market, by Disease Type, 2022 vs 2030
  • 4.3. Metabolic Disorders Therapeutics Market, by Product, 2022 vs 2030
  • 4.4. Metabolic Disorders Therapeutics Market, by Region, 2022 vs 2030

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Growing awareness regarding the treatment of metabolic disorders
      • 5.1.1.2. Prevalence of various metabolic diseases in the growing population
      • 5.1.1.3. Improvements in metabolic disorder testing and diagnosis
    • 5.1.2. Restraints
      • 5.1.2.1. High cost of therapeutics and lack of reimbursements
    • 5.1.3. Opportunities
      • 5.1.3.1. Rise in the funding for the development of novel therapeutic approaches
      • 5.1.3.2. Potential of gene therapy for metabolic disorder treatment
    • 5.1.4. Challenges
      • 5.1.4.1. Strict government approval standards and regulations
  • 5.2. Market Trends
  • 5.3. Cumulative Impact of COVID-19
  • 5.4. Cumulative Impact of Russia-Ukraine Conflict
  • 5.5. Cumulative Impact of High Inflation
  • 5.6. Porter's Five Forces Analysis
    • 5.6.1. Threat of New Entrants
    • 5.6.2. Threat of Substitutes
    • 5.6.3. Bargaining Power of Customers
    • 5.6.4. Bargaining Power of Suppliers
    • 5.6.5. Industry Rivalry
  • 5.7. Value Chain & Critical Path Analysis
  • 5.8. Regulatory Framework
  • 5.9. Client Customization

6. Metabolic Disorders Therapeutics Market, by Disease Type

  • 6.1. Introduction
  • 6.2. Diabetes
  • 6.3. Hypercholesterolemia
  • 6.4. Lysosomal Storage Disease
  • 6.5. Obesity

7. Metabolic Disorders Therapeutics Market, by Product

  • 7.1. Introduction
  • 7.2. Globoid Leukodystrophy
  • 7.3. Hepatic Encephalopathy
  • 7.4. Metachromatic Leukodystrophy

8. Americas Metabolic Disorders Therapeutics Market

  • 8.1. Introduction
  • 8.2. Argentina
  • 8.3. Brazil
  • 8.4. Canada
  • 8.5. Mexico
  • 8.6. United States

9. Asia-Pacific Metabolic Disorders Therapeutics Market

  • 9.1. Introduction
  • 9.2. Australia
  • 9.3. China
  • 9.4. India
  • 9.5. Indonesia
  • 9.6. Japan
  • 9.7. Malaysia
  • 9.8. Philippines
  • 9.9. Singapore
  • 9.10. South Korea
  • 9.11. Taiwan
  • 9.12. Thailand
  • 9.13. Vietnam

10. Europe, Middle East & Africa Metabolic Disorders Therapeutics Market

  • 10.1. Introduction
  • 10.2. Denmark
  • 10.3. Egypt
  • 10.4. Finland
  • 10.5. France
  • 10.6. Germany
  • 10.7. Israel
  • 10.8. Italy
  • 10.9. Netherlands
  • 10.10. Nigeria
  • 10.11. Norway
  • 10.12. Poland
  • 10.13. Qatar
  • 10.14. Russia
  • 10.15. Saudi Arabia
  • 10.16. South Africa
  • 10.17. Spain
  • 10.18. Sweden
  • 10.19. Switzerland
  • 10.20. Turkey
  • 10.21. United Arab Emirates
  • 10.22. United Kingdom

11. Competitive Landscape

  • 11.1. FPNV Positioning Matrix
  • 11.2. Market Share Analysis, By Key Player
  • 11.3. Competitive Scenario Analysis, By Key Player

12. List of Company Mentioned

13. Appendix

  • 13.1. Discussion Guide
  • 13.2. License & Pricing